4E4 Stock Chart & Stats
€0.20
€2.84(70.70%)
At close: 4:00 PM EST
€0.20
€2.84(70.70%)
Day’s Range― - ―
52-Week Range€0.02 - €1.90
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€12.83M
Enterprise Value€16.37
Total Cash (Recent Filing)€8.19M
Total Debt (Recent Filing)€10.69M
Price to Earnings (P/E)―
Beta-3.21
Next Earnings
Nov 12, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.04
Shares Outstanding41,064,144
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.12
Price to Sales (P/S)181.35
P/FCF Ratio-5.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.29Price Target Upside544.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.26
Revenue Forecast (FY)€4.43M
Bulls Say, Bears Say
Bulls Say
Strong TTM Revenue GrowthThe sharp increase in trailing revenue indicates that Scienture is expanding product sales or commercialization activity. If growth persists, a larger revenue base could improve operating leverage, support broader market access, and provide a foundation for eventual profitability.
Positive Gross MarginA positive gross margin shows that the company retains economics after direct product costs, an essential base for a pharmaceutical commercialization model. Although current overhead overwhelms this contribution, maintaining or improving gross margin could support future operating leverage.
Moderate Current LeverageModerate debt relative to equity gives Scienture more financial flexibility than a highly leveraged structure would provide. Lower current leverage can reduce interest pressure and preserve capacity to fund commercialization or development, provided the equity base remains stable.
Bears Say
Severe Persistent Operating LossesDeep losses across net income, EBIT, and EBITDA show that current revenue is not covering the company’s operating cost structure. Without substantial margin improvement, continued growth may increase absolute losses and delay the transition to sustainable earnings.
Heavy Cash BurnLarge negative operating and free cash flow means Scienture is consuming cash rather than funding operations internally. Ongoing burn can create recurring financing needs, reduce strategic flexibility, and make execution more dependent on access to additional capital.
Unstable Capital Structure And Negative ReturnsThe contrast between historical high leverage and the current capital structure reduces confidence that the balance sheet is stable over time. Slightly negative ROE also indicates that shareholder capital is not yet producing sustainable returns from the business.
Scienture Holdings News
4E4 FAQ
What was Scienture Holdings’s price range in the past 12 months?
Scienture Holdings lowest stock price was €0.02 and its highest was €1.90 in the past 12 months.
What is Scienture Holdings’s market cap?
Scienture Holdings’s market cap is €12.83M.
When is Scienture Holdings’s upcoming earnings report date?
Scienture Holdings’s upcoming earnings report date is Nov 12, 2026 which is in 63 days.
How were Scienture Holdings’s earnings last quarter?
Scienture Holdings released its earnings results on Aug 14, 2026. The company reported -€0.06 earnings per share for the quarter, beating the consensus estimate of -€0.077 by €0.017.
Is Scienture Holdings overvalued?
According to Wall Street analysts Scienture Holdings’s price is currently Undervalued.
Does Scienture Holdings pay dividends?
Scienture Holdings does not currently pay dividends.
What is Scienture Holdings’s EPS estimate?
Scienture Holdings’s EPS estimate is -0.05.
How many shares outstanding does Scienture Holdings have?
Scienture Holdings has 41,064,144 shares outstanding.
What happened to Scienture Holdings’s price movement after its last earnings report?
Scienture Holdings reported an EPS of -€0.06 in its last earnings report, beating expectations of -€0.077. Following the earnings report the stock price went up 6.14%.
Which hedge fund is a major shareholder of Scienture Holdings?
Currently, no hedge funds are holding shares in DE:4E4
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Scienture Holdings
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.
4E4 Stock 12 Month Forecast
Average Price Target
€1.29
▲(544.32% Upside)